Distinguished Scientist, Clinical Pharmacology
Genentech
Pacifica, California, United States
David Turner is currently a Distinguished Scientist in the Department of Clinical Pharmacology at Genentech, since September 2021. With over a decade of experience in Clinical Pharmacology (CP) and Modeling and Simulation (M&S), David has played a pivotal role in various global regulatory submissions and health authority interactions. During his time with Merck, his work on the anti-PD1 treatment pembrolizumab in NSCLC has been particularly influential, helping to establish it as a new standard of care in metastatic NSCLC.
Prior to joining Genentech, David worked at GSK, where he served as a clinical pharmacology lead for oncology programs and led an MBMA capability build for benchmarking internal oncology assets against external standard-of-care agents. Since joining Genentech, David has led CP efforts for the mosunetuzumab (bispecific anti-CD20/CD3) program, significantly impacting its global regulatory submissions and helping secure its first global approvals in relapsed/ refractory follicular lymphoma.
Throughout his career, David has authored more than 40 publications, delivered 3 oral presentations, and presented more than 20 posters. His work in the area of exposure-response (E-R) confounding has been acknowledged as landmark and practice-changing.
In the upcoming scientific conference session, David will underscore the importance of recognizing various potential sources of E-R confounding, using past examples from oncology biologics. The session will emphasize the importance of closely examining cause-and-effect relationships and advocate for continued research to address future E-R confounding issues that will challenge the field.
Disclosure(s): Genentech: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Wednesday, November 13, 2024
9:00 AM – 10:30 AM MST
